No deal for Merck and Seagen yet as talks stall over buyout price — report
Two Mondays have come and gone without Merck’s hotly-rumored takeover of Seagen, keeping observers waiting. And according to a new Bloomberg report, that’s because the two sides have yet to agree on a price.
Talks between Merck and Seagen have stalled over the acquisition price, the news wire reported, citing anonymous insiders. The discussion could still resume and lead to a deal, they added, although it clearly also may not. Seagen shares tumbled almost 7% to $153 in light of the report.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.